ExcelFin Acquisition — SPAC Merger (June 2023)
51 slides from ExcelFin Acquisition's SPAC merger presentation, Jun 26, 2023
Slide 1: Baird Medical Investor Presentation June 2023
Baird Medical Baird Medical Baird Medical INVESTOR PRESENTATION JUNE 2023
Slide 2: Disclaimer
Baird Medical This presentation (together with oral statements made in connection herewith, this “Presentation”) is for informational purposes only to assist interested parties in making their own evaluation with respect to the proposed business combination (the “Business Combination”) between Excel
Slide 3: Disclaimer (continued)
Baird Medical The distribution of this Presentation may also be restricted by law and persons into whose possession this Presentation comes should inform themselves about and observe any such restrictions . The recipient acknowledges that it is (a) aware that the United States securities laws prohib
Slide 4: Additional Information
Baird Medical Additional Information . In connection with the proposed Business Combination, Baird Medical intends to file with the SEC a registration statement on Form F - 4 containing a preliminary proxy statement/prospectus of ExcelFin , and after the registration statement is declared effective,
Slide 5: Baird Medical and ExcelFin Presenters
Baird Medical Baird Medical and ExcelFin Presenters 5 Brian Sun COO / EVP • Currently serving as the Managing Director for Golden Vision Capital • Served as Director of Corporate Development at SGS, Executive Director M&A at CMBNY, Vice President at Lazard, and Director of M&A at AES Corp • Prior in
Slide 6: Industry-Leading Sponsorship
Baird Medical Industry - Leading Sponsorship Strategic Partnership Combining GFC’s Global Investment Footprint and Fin VC’s Deep Domain Expertise Grand Fortune Capital x An investment firm owned by Jackson Wijaya x ExcelFin is affiliated with GVC, an investment group that completed a series of signi
Slide 7: Why Baird Medical
Baird Medical MARKET LEADER – A leading developer and provider of a microwave ablation (MWA) medical device for treating thyroid nodules and breast lumps with ~35% market share in China 1 STRONG FINANCIAL PROFILE – Significant recurring revenue from manufacturing and selling MWA consumables, boastin
Slide 8: Business Combination Summary
Baird Medical Business Combination Summary 8 1. The pro forma figures are based on a number of assumptions, and actual results may vary significantly from our expectation s. See Disclaimer – “Forward - Looking Statements”. For more information see slide 41, entitled “Transaction Summary” ▪ ExcelFin
Slide 9: Company Overview
Baird Medical Baird Medical Company Overview
Slide 10: Baird Medical At-A-Glance
Baird Medical Baird Medical At - A - Glance 10 R&D CAPABILITIES Note: These projections are based on a number of assumptions, and actual results may vary significantly from our expectations. See Dis claimer – “Projections” 1. According to Frost & Sullivan Report as of June 2023. Based on sales reven
Slide 11: How Our MWA Medical Devices Work
Baird Medical The peristaltic pump will be turned on and allow the circulation of cooling saline, to prevent and reduce damage to other parts of the patient’s body MWA Therapeutic Apparatus MWA Needles (Disposable) How Our MWA Medical Devices Work Cooling Saline Peristaltic Pump MWA Therapeutic Appa
Slide 12: Ultrasound Guided MWA: A Preferred Treatment with a Significant TAM
Baird Medical Ultrasound Guided MWA: A Preferred Treatment with a Significant TAM 12 SIGNIFICANT MARKET WITH EXPECTED ROBUST GROWTH ~$4 – $10 Billion Potential size of the MWA market for benign thyroid nodules in China 1 ~6 – 14 Million Total patients eligible for MWA to treat benign thyroid nodules
Slide 13: Total Potential Addressable Market: $4-$10 Billion
Baird Medical 19.8 21.1 22.4 23.7 25.1 27.0 29.1 31.0 33.2 35.5 38.1 13.8 14.7 15.8 17.0 18.6 20.3 21.9 23.7 25.7 28.1 30.7 2016 2017 2018 2019 2020 2021 2022E 2023E 2024E 2025E 2026E Incidence Rates (%) of Thyroid Nodules US China TOTAL POTENTIAL ADDRESSABLE MARKET: $4 – $10 BILLION • Thyroid nodul
Slide 14: Established Multi-Channel Sales Strategy Leads to Broad Market Reach
Baird Medical 51% 62% 2019 2022 Established Multi - Channel Sales Strategy Leads to Broad Market Reach 14 WELL - ESTABLISHED SALES MODEL… Hospitals Distributors Sales to distributors 431 Hospitals purchasing our products 256 Grade III hospitals 60 Hospitals under direct sales % OF SALES DIRECTLY TO
Slide 15: Academic Conferences and Events
Baird Medical The 10th China Conference on Interventional Oncology (CCIO 2019) and 2019 Chinese National Congress on Intervention Oncology 2019 Annual Meeting of Breast and Thyroid Surgery Study Group under the General Surgery Committee of Hunan Medical Association China Embolisation Therapy, CET 20
Slide 16: Four Pillar Marketing and Brand Building Strategy
Baird Medical Baird Medical Four Pillar Marketing and Brand Building Strategy 16 Baird Medical strives to be a key hub for medical knowledge and technology, leveraging its significant networks with leading hos pitals, surgeons, medical associations, organizations, and the National Health Commission
Slide 17: End Users Ranked in the Top Hospitals in China
Baird Medical Baird Medical’s End Users Ranked in The 100 Top Hospital in China (Fudan List)* • Following the top - down approach , Baird Medical end users started with top tier Grade III Hospitals in affluent South China provinces, and subsequently has been expanding to lower tier hospitals based o
Slide 18: Awards
Baird Medical Baird Medical Awards 18 2021 High and New Technology Enterprises ( Baide Suzhou) Jiangsu Provincial Department of Science and Technology, Jiangsu Provincial Department of Finance and Jiangsu Provincial Administration of Taxation of the STA 2020 China Law - abiding and Trustworthy Medic
Slide 19: Demonstrated Success Expanding into Tier I Provinces
Baird Medical 31 51 59 68 2019 2020 2021 2022 29 43 37 42 2019 2020 2021 2022 72 61 58 111 2019 2020 2021 2022 NUMBER OF HOSPITALS PENETRATED IN GUANGDONG NUMBER OF HOSPITALS PENETRATED IN SHANGHAI / FUJIAN / JIANGXI Demonstrated Success Expanding into Tier I Provinces 19 NUMBER OF HOSPITALS PENETRA
Slide 20: Opportunity to Capture Significant Growth in Tier 2 and 3 Provinces
Baird Medical 57 50 52 86 2019 2020 2021 2022 63 69 98 124 2019 2020 2021 2022 Opportunity to Capture Significant Growth in Tier 2 and 3 Provinces 20 Tier 2 Provinces: Anhui, Hunan, Heilongjiang, Jilin, Liaoning, Hubei, Shandong, Guangxi, and Beijing Tier 3 Provinces: Jiangsu, Henan, Shaanxi, Shanxi
Slide 21: Top Player in China's MWA Market
Baird Medical Top 3 Player in China’s MWA Market Company A Company B Company C 34.8% Company A 30.4% Company B 14.7% Company C 12.1% MWA medical device enterprises require specialized technological expertise and distinct competitive technological advantages High Barriers - to - Entry 36.8% 20.9% 19.
Slide 22: Product Pipeline
Baird Medical Product / Product Set Approved / Planned Indication Stage Location Registered Expected Launch Year Development Testing Clinical Trial Preparation Clinical Trial Registration Commercialization MWA therapeutic apparatus and/or MWA needles (disposable) Liver Cancer China Launched Thyroid
Slide 23: Investment Highlights
Baird Medical Baird Medical Investment Highlights
Slide 24: Key Investment Highlights
Baird Medical Key Investment Highlights 24 1 Leader in an Underserved Market • Ranked 1 st among MWA medical device providers in thyroid nodule and breast lump treatment with ~35% market share in China 1 2 Extensive Sales & Distribution Network • Nationwide coverage of 21 provinces and partnership w
Slide 25: Leader in an Underserved Market
Baird Medical 210 521 2022 2026E ($M) CAGR 25.5% 0.4 0.9 2022 2026E 0.7 1.4 2022 2026E TARGET HIGH MARKET DEMAND WITH LEAD POSITION 25 Leader in an Underserved Market 1 Our MWA medical devices primarily target specialty areas with significant efficacy Benign Tumors : Thyroid Nodules Breast Lumps Mal
Slide 26: Extensive Sales & Distribution Network
Baird Medical 26 Extensive Sales & Distribution Network 2 Current Operations Expansion Plans Average growth rate of hospital end users within current provinces is 20% from 2019 to 2022, leaving tremendous opportunity for growth and expansion, particularly in Tier 2 & 3 PENETRATION RATES Baird Medica
Slide 27: Strong R&D Capabilities: Registered Patents
Baird Medical 38 Registered Patents • 38 patents under application and had obtained ( i ) one registration certificate for Class III medical devices and (ii) two registration certificates for Class II medical device (one of which has already expired on March 25, 2023 however, a new registration cert
Slide 28: Delivering Value to all Stakeholders in the Value Chain
Baird Medical 28 Delivering Value to all Stakeholders in the Value Chain 4 Private & Public Insurers x Early MWA treatment can decrease medical expenses for private insurers and the government x Covered by the national medical insurance in Guangdong Province with a reimbursement rate up to 80% x Lik
Slide 29: Multiple Levers for Growth
Baird Medical UPGRADE OUR PLANT AND IMPROVE THE AUTOMATION LEVEL • Carry out fitting - out works of the Suzhou Plant to commence our production in the Suzhou Plant • Automate certain production steps by installing various types of intelligent machinery and equipment • Provide training to our product
Slide 30: Medium to Long-Term Global Growth Strategy
Baird Medical 30 Medium to Long - Term Global Growth Strategy x The founders of Baird Medical have long planned to develop the company into a global medical device , and extend the treatment option to patients outside of China x Becoming a public company in the US is an integral part of the company’
Slide 31: Experienced Management Team
Baird Medical Experienced Management Team 6 MS. HAIMEI WU Founder, ED, Chairlady of the Board and CEO • Mainly responsible for the overall corporate strategies, management of our Group’s business operations and development • Over 20 years of experience in the medical devices industry • Completed adv
Slide 32: Highly Regarded Independent Board Directors
Baird Medical Highly Regarded Independent Board Directors 32 • Leading physician scientist, clinical thyroid specialist and tenured Professor of Medicine, Oncology and Cellular and Molecular at the Johns Hopkins University School of Medicine • Main clinical and research interests are thyroid disease
Slide 33: Industry Overview
Baird Medical Baird Medical Industry Overview
Slide 34: Comparison of Tumor Ablation Technologies
Baird Medical MWA RADIOFREQUENCY ABLATION (RFA) CRYOABLATION (CRA) LASER ABLATION (LSA) Principle • Microwave rapidly creates heat for ablation process • High - frequency electrical currents create heat for ablation • Gas throttling effect of argon/helium for ablation • He - Ne laser or excimer lase
Slide 35: MWA Market is Poised for Significant Growth
Baird Medical x MWA therapy can be applied to a wide range of diseases including thyroid nodule and cancer, breast lump and cancer, liver cancer, pulmonary nodule and lung cancer Thyroid Nodule Liver Cancer Pulmonary Nodules Lung Cancer Breast Lump Other MWA Market is Poised for Significant Growth 3
Slide 36: Broader Medical Device Market in China
Baird Medical $22 $25 $30 $34 $39 $49 $52 $53 $56 $61 $66 $34 $40 $50 $57 $66 $83 $90 $93 $98 $108 $117 $56 $65 $80 $90 $106 $132 $142 $146 $155 $169 $183 2016 2017 2018 2019 2020 2021 2022 2023E 2024E 2025E 2026E Medical Instruments Medical Consumables Broader Medical Device Market in China ($USD B
Slide 37: Financial Summary
Baird Medical Baird Medical Financial Summary
Slide 38: Financial Summary
Baird Medical $17.2 $19.5 $25.3 $36.6 2021 2022 2023E 2024E $27.5 $35.2 $44.5 $62.5 2021 2022 2023E 2024E 304 431 527 660 2021 2022 2023E 2024E Financial Summary 38 HOSPITALS USING BAIRD MEDICAL’S PRODUCTS REVENUE ($M) ADJUSTED EBITDA ($M) 1 Note: These projections are based on a number of assumptio
Slide 39: Operational Benchmarking
Baird Medical 56.8% 27.9% 28.8% 26.0% 5.0% 28.9% 23.9% 17.7% 25.5% (20.6%) 15.6% 58.5% 27.7% 29.6% 26.6% 5.1% 28.6% 25.3% 19.5% 26.1% (1.7%) 21.2% 26.4% 11.1% 9.8% 8.5% 7.0% 1.3% (0.5%) (2.0%) (9.4%) 20.4% 14.0% 40.3% 14.5% 8.1% 7.3% 4.8% 4.4% 5.6% 3.6% 4.2% 34.1% 14.3% Operational Benchmarking REVE
Slide 40: Valuation Benchmarking
Baird Medical 14.6x 8.7x 22.0x 24.3x 26.6x 15.1x 17.3x 9.5x 19.4x NM 18.4x 10.1x 7.6x 19.8x 22.2x 24.7x 14.6x 15.5x 8.3x 18.1x NM 11.8x 0.39x 0.75x 1.91x 2.55x NM NM 2.45x 0.80x NM NM 0.32x 0.27x 0.66x 1.72x 2.33x NM NM 2.19x 0.70x NM NM 0.21x Valuation Benchmarking 2023 Multiples 2024 Multiples EV
Slide 41: Transaction Summary
Baird Medical 6.8% 12.1% 81.1% Transaction Summary 41 SOURCES & USES KEY HIGHLIGHTS Betters Medical Shareholders SPAC Investors Sponsor Shares Pro Forma Capitalization PF Share Outstanding (M) 36.3 Share Price at Merger ($) $10.20 Pro Forma Equity Value ($M) $370 (+) Existing Net Debt ($M) $10 ( - )
Slide 42: Appendix
Baird Medical Baird Medical Appendix
Slide 43: Adjusted EBITDA Reconciliation
Baird Medical Adjusted EBITDA Reconciliation 43 ($M) 2021 2022 Net Income $12.3 $12.6 (+) Depreciation 1.1 0.8 (+) Income Tax 2.4 2.5 (+) Interest Expenses 0.2 0.3 (+) Listing Expenses 2.2 3.6 (-) Other Income (Excluding Interest Income / Expenses) (1.0) (0.3) Adjusted EBITDA $17.2 $19.5 Net Income
Slide 44: Summary of Exchange Rates
Baird Medical Summary of Exchange Rates 44 For All Frost & Sullivan Report Figures 2016 2017 2018 2019 2020 2021 2022 2023E 2024E 2025E 2026E Exchange Rate of 1 USD to RMB 6.642 6.752 6.617 6.899 6.898 6.452 6.726 7.240 7.460 7.380 7.280 For Baird Medical Projections 2020 2021 2022 2023E 2024E Excha
Slide 45: Product Categories
Baird Medical PRODUCT CATEGORY CLASSIFICATION FEATURES SAMPLE PICTURES MWA needles Long MWA needles Class II and/or Class III • Materials of needle: tin - phosphor bronze for the tip; stainless steel for the rod; with PTFE coating • Microwave frequency: 915 MHz or 2,450 MHz • Specifications: length
Slide 46: Products Under Development
Baird Medical Products Under Development PRODUCT CATEGORY CLASSIFICATION FEATURE, APPLICATIONS AND BENEFITS STAGE OF DEVELOPMENT EXPECTED LAUNCH DATE MWA - ultrasound integrated therapeutic apparatus Class III • Equipped with ultrasound scanner for locating the tumor precisely during a MWA treatment
Slide 47: Risk Factors
Baird Medical Risk Factors 47 The summary of risk factors provided below should be carefully considered in conjunction with the risks and uncertainties des cri bed in the “Risk Factors” section of the registration statement on Form F - 4 to be filed by Baird Medical Investment Holdings Limited (the
Slide 48: Risk Factors (cont'd): Doing Business in China
Baird Medical Risk Factors (cont’d) 48 Risks Related to Doing Business in China • Medical device manufacturers in China are subject to extensive safety regulations and requirements, which can lead to increas ed compliance costs and heightened risks of inadvertent incidents of noncompliance. Baird Me
Slide 49: Risk Factors (cont'd): ExcelFin and the Business Combination
Baird Medical Risk Factors (cont’d) 49 Risks Relating to ExcelFin, PubCo and the Business Combination • If ExcelFin does not consummate the Business Combination by the termination date of October 25, 2023, ExcelFin will have to c eas e all operations except to wind up, redeem all of its public share
Slide 50: Risk Factors (cont'd)
Baird Medical Risk Factors (cont’d) 50 • The benefits of the potential Business Combination may not be realized to the extent currently anticipated by ExcelFin and Ba ird Medical, or at all. If the Business Combination’s benefits do not meet expectations of investors, stockholders or analysts, the m
Slide 51: Thank you
Baird Medical Baird Medical Thank you